Journal article
The ketogenic diet is effective for refractory epilepsy associated with acquired structural epileptic encephalopathy
MM Villaluz, LB Lomax, T Jadhav, JH Cross, IE Scheffer
Developmental Medicine and Child Neurology | WILEY | Published : 2018
DOI: 10.1111/dmcn.13687
Abstract
Aim: Ketogenic diet therapies have proven efficacy for refractory epilepsy. There are many reports of their use in the genetic developmental and epileptic encephalopathies; however, little attention has been paid as to whether the diet is also effective in individuals with an acquired structural aetiology. We observed remarkable efficacy of the diet in two patients with hypoxic-ischaemic encephalopathy. We then analysed our cases with refractory structural epilepsies of acquired origin to characterize their response to the ketogenic diet. Method: The classical ketogenic diet was implemented with dietary ratios of 3:1 to 4.4:1. Seizure frequency at 1 month, 3 months, 6 months, 1 year, and 2 y..
View full abstractGrants
Awarded by Royal College of Physicians and Surgeons of Canada
Funding Acknowledgements
Dr Villaluz received Fellowship support from the Epilepsy Society of Australia. Dr Boisse Lomax received Fellowship support from the Detweiler Travelling Fellowship (Royal Canadian College of Physicians and Surgeons) and the Cecil Patience Reid Fellowship (Queen's University Faculty of Health Sciences). Funding was also provided by the National Health and Medical Research Council of Australia, and by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. Dr Scheffer has served on scientific advisory boards for UCB and Janssen-Cilag Europe, Middle-East and Africa (EMEA); may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has received speaker honoraria from Athena Diagnostics, UCB, GlaxoSmithKline, Biocodex, and Janssen-Cilag EMEA; and has received funding for travel from Athena Diagnostics, UCB, Biocodex, GlaxoSmithKline, and Janssen-Cilag EMEA. Dr Cross has received speaker's or consultancy fees or research grants, or both, paid to her department from Esai, GlaxoSmithKline, Sanofi, UCB, Shire, Vitaflo, Nutricia, and has participated as an investigator in clinical trials for GW Pharma and Zogenix. The remaining authors have stated that they had no interests which might be perceived as posing a conflict or bias.